Controversies in Neuro-Oncology

Bevacizumab for Recurrent Glioma - A Personal View

Author(s): Roger Stupp

Pp: 133-139 (7)

DOI: 10.2174/978160805132811001010133

* (Excluding Mailing and Handling)


Treatment of recurrent glioma remains a therapeutic challenge. Unprecedented high response rates associated with rapid clinical improvement have been observed. Despite the absence of definitive data and while definitive trial has not even been started, regulatory approval was requested. And while the United States Food and Drug Administration granted accelerated approval based on 2 small uncontrolled phase II trials, the European Medicines Agency rejected the application.

Related Journals
Related Books
© 2024 Bentham Science Publishers | Privacy Policy